What counseling should be provided to a patient when the allergist recommends allergy shots (subcutaneous immunotherapy)?

Counseling for Allergy Shots (Subcutaneous Immunotherapy)

When counseling a patient about allergy shots, emphasize that this is a 3+ year commitment requiring weekly injections initially, then monthly maintenance, with proven efficacy for allergic rhinitis and asthma, but carrying a small risk of severe allergic reactions including anaphylaxis—making it essential they wait 30 minutes after each injection and avoid shots when asthma is poorly controlled.

Critical Safety Information

Anaphylaxis Risk and Timing

• Most severe reactions occur within 30 minutes of injection 1
• In fatal cases analyzed, 11 of 17 patients experienced onset within 20 minutes 1
• The 30-minute waiting period after each injection is non-negotiable—4 patients who died did not wait after their injection 1
• Reactions can be life-threatening, though fatal reactions are rare when proper precautions are followed 2, 3

Absolute Contraindications to Receiving Shots

Uncontrolled asthma is the single most important risk factor for fatal reactions 1. Counsel patients they should NOT receive their injection if:

• Their asthma is symptomatic or poorly controlled that day
• FEV1 is less than 80% of predicted value (in one study, 73.3% of patients with FEV1 <80% had asthmatic reactions during immunotherapy versus only 12.6% with FEV1 >80%) 1
• They are experiencing an exacerbation of allergic symptoms
• They are taking beta-blockers (increases risk of severe reactions and makes treatment more difficult) 1

Additional Risk Factors

• High degree of hypersensitivity on testing 1
• Injections from newly prepared vials 1
• Previous systemic reactions to immunotherapy 1

Treatment Duration and Commitment

Minimum 3-year treatment course is required 4:

• Buildup phase: Weekly injections for approximately 3-4 months, gradually increasing doses
• Maintenance phase: Monthly injections for the remainder of treatment
• Total commitment: 3+ years for disease-modifying effects

Adherence Challenges

The most common reasons patients discontinue treatment 5:

• Relocation for education, work, or travel (53.45%)—discuss life plans before starting
• Perceived lack of efficacy (17.24%)—set realistic expectations about timeline
• Time constraints (8.62%)—ensure they can commit to the schedule
• Pregnancy/gynecological conditions (6.90%)—discuss reproductive plans upfront

Expected Benefits

For allergic rhinitis: Moderate-quality evidence supports symptom reduction in adults with seasonal and house dust mite allergies 6

For asthma with allergic rhinitis: Conditional recommendation with moderate-quality evidence for symptom reduction 6

Note: Some guidelines (British Thoracic Society, GINA 2016) state efficacy in asthma is limited, reflecting ongoing debate 6

What to Expect During Treatment

Local Reactions

• Swelling, redness, itching at injection site are common
• Usually mild and self-limited

Systemic Reactions

Graded by severity 1:

• Grade 1: Single organ system (skin itching, hives, flushing)
• Grade 2: Multiple organ systems (generalized hives + mild respiratory symptoms)
• Grade 3: Lower respiratory symptoms not responding to inhaled bronchodilator
• Grade 4: Respiratory failure with/or without loss of consciousness
• Grade 5: Death

Overall systemic reaction rate is low (0.71-0.93% per injection) 7, but patients must recognize symptoms early.

Pre-Injection Screening

Before each injection, staff will assess 1:

• Current asthma control and symptoms
• Any new medications (especially beta-blockers)
• Recent illness or infection
• Current allergy symptom severity

Critical Safety Measures

Patients must:

• Wait full 30 minutes after every injection
• Report ANY symptoms immediately (itching, throat tightness, breathing difficulty, dizziness)
• Carry epinephrine auto-injector if prescribed
• Ensure asthma is well-controlled before each visit
• Inform staff of any medication changes

Common pitfall: Patients feeling fine after 10-15 minutes and wanting to leave—this is when many severe reactions occur. The 30-minute rule has no exceptions.

Disease-Modifying Potential

Unlike medications that only treat symptoms, immunotherapy can alter the underlying immune response and provide lasting benefit even after treatment completion 8. This represents the primary rationale for the lengthy treatment course and commitment required.